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Oligonucleotides (ONs), and their chemically modified mimics, are now routinely used in the laboratory as
a means to control the expression of fundamentally interesting or therapeutically relevant genes. ONs are
also under active investigation in the clinic, with many expressing cautious optimism that at least some
ON-based therapies will succeed in the coming years. In this review, we will discuss several classes of
ONs used for controlling gene expression, with an emphasis on antisense ONs (AONs), small interfering
RNAs (siRNAs), and microRNA-targeting ONs (anti-miRNAs). This review provides a current and detailed
account of ON chemical modification strategies for the optimization of biological activity and therapeutic
application, while clarifying the biological pathways, chemical properties, benefits, and limitations of oligo-
nucleotide analogs used in nucleic acids research.The concept of using synthetic oligonucleotides (ONs) to control
the expression of specific genes dates back to the late 1970s,
when Zamecnik and Stephenson first demonstrated targeted
gene silencing using a short synthetic oligonucleotide (Zamecnik
and Stephenson, 1978; Stephenson and Zamecnik, 1978). From
these seminal studies emerged the ‘‘antisense’’ approach for tar-
geted gene silencing. Here, an exogenous synthetic ON (termed
an antisense ON, or AON) complementary to a target mRNA is
introduced into cells with the intent to block gene expression
through either translational inhibition or enzymatic cleavage of
the mRNA target. AON-based therapeutics have been under
clinical investigation for more than 30 years, achieving one
approved drug (Fomivirsen/Vitravene). The gradual progress of
AON therapeutic development has led to some hesitation
regarding the viability of the platform. Subsequent to Zamecnik’s
discoveries, elucidation of the RNA interference (RNAi) pathway
for modulation of gene expression, and the role of small inter-
fering RNAs (siRNAs) in the process, changed our understanding
of posttranscriptional gene expression control, and renewed
excitement in the nucleic acid therapeutics community (Fire
et al., 1998; Elbashir et al., 2001).
It is well established that properly designed AONs or siRNAs
can cause cleavage of specificmessenger RNA (mRNA) strands,
taking advantage of endogenous cellular pathways to potently
silence the expression of specific genes. These synthetic ON-
directed approaches target mRNAs directly, before translation,
eliminating the need for protein/enzyme inhibition using small
molecules. Although siRNAs and AONs are perhaps the most
commonly discussed ON-based agents under development,
they are certainly not the only promising short synthetic ONs.
Other relevant ON agents includemicroRNA-targeting ONs (anti-
miRNAs) and antagomirs (discussed below), aptamers (Keefe
et al., 2010), DNA/RNAzymes (Chan and Khachigian, 2009;
Mulhbacher et al., 2010), exon-skipping and splice-switching
compounds (Kole et al., 2012; Saleh et al., 2012), and immunos-
timulatory nucleic acids (Barchet et al., 2008).
The most significant of obstacles impeding the path to ON
therapeutics include (1) their poor extracellular and intracellularChemistry & Biolostability, (2) low efficiency of intracellular delivery to targets cells
or tissues, and (3) the potential for ‘‘off-target’’ gene silenc-
ing, immunostimulation, and other side effects. Fortunately, in
attempts to overcome the therapeutically limiting features of
DNA and RNA, a vast array of ON chemical modifications
has been developed. These nucleic acid analogs are often ratio-
nally designed, allowing specific alterations to many of the in-
herent properties of ONs affecting their biological application
and potency (e.g., target binding affinity, nucleoside/nucleo-
tide/duplex conformation, hydrophobicity, enzyme interaction,
nuclease resistance, and immunostimulatory properties).
Keeping with the aim of this review, biological pathways
relevant to AON, siRNA, and anti-miRNA ON agents are briefly
described, providing a foundation for subsequent discussions
of therapeutic ON analogs. The underlying chemistries driving
innovative strategies to optimize ON therapeutics are the focus
of this review, and are best considered in relation to the biolog-
ical pathways in which these ONs function. Concepts essential
to the design of AONs, siRNAs, and anti-miRNAs are presented,
along with perspectives on the current and future state of the art.
Combining advances in biological understanding with chemical
know-how is key to advancing this promising field.
Biological Pathways
Although specific details involved in some of the biological path-
ways described remain to be elucidated, the fundamental events
of these processes are now understood to the point that chem-
ical modifications can be utilized in an effort to enhance the
potency and therapeutic potential of ONs. Here, AON-mediated
gene silencing, miRNA- and siRNA-induced gene knockdown
through RNAi, and gene expression modulation by anti-miRNAs
are introduced. Focus is given to mechanism and nucleic
acid-enzyme interactions where possible, such that subsequent
discussions of oligonucleotide modifications and pathway com-
patibility can be made.
AON-Mediated Gene Silencing
AONs are perhaps the oldest andmost studied class of gene-tar-
geting ONs. Indeed, AONs have been reported on and studiedgy 19, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 937
Figure 1. Fundamentals of mRNA-
Targeting by AONs
Exogenously introduced AONs can recognize and
bind to target mRNA sequences. This can result in
either mRNA cleavage via recruitment of RNase
H1 (in humans), or translational arrest. In both
situations, the result is downregulation of gene
expression. Although shown in the cytoplasm,
RNase H may also function in the nucleus.
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pathway appeared. AON-based therapeutics have seen periods
of both optimism and pessimism, perhaps partly owing to the
longer than anticipated development time (Watts and Corey,
2012). Nonetheless, significant progress has been made in
recent years, with one approved drug on the market (Fomi-
versen) and more than 20 candidates in early to late-stage clin-
ical trials (Sanghvi, 2011; Bennett and Swayze, 2010; Watts
and Corey, 2012).
A wide variety of RNA-targeting ONs can be considered as
AONs, although they may act through different mechanisms.
Specific and strong AON recognition and binding to the
mRNA target is accomplished through Watson-Crick base
pairing, which may or may not be augmented by chemical
modifications to the AON internucleotide phosphate linkages,
backbone sugars, or nucleobases. The majority of AONs can
be divided into one of two groups: those that direct cleavage
of the target mRNA, and those that alter mRNA translation
without causing mRNA cleavage. The basic concepts of these
two modes of action are outlined in Figure 1. In both cases,938 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd All rights reservedthe cellular target of the AON is a region
of the mRNA from the gene of interest.
Initially, the concept of gene silencing
AONs that do not induce mRNA cleav-
age as part of their biological function
appears to be quite straightforward:
AONs are chemically modified to have
strong binding affinity to their mRNA
targets, and function by binding RNA
tightly, preventing ribosomal assembly
(Bennett and Swayze, 2010). Trans-
lational inhibition by these AONs is
difficult to detect and measure (Bennett
and Swayze, 2010), but can indeed be
detected and assayed (e.g., via polysome
profiling experiments) (Baker et al., 1997).
However, the situation can become
considerably more complex. In some
cases, AONs can be designed to bind
mRNA regions that prevent ribosomal
assembly at the 50 cap (Bennett and
Swayze, 2010), prevent polyadenylation
during mRNA maturation (Bennett and
Swayze, 2010), or even affect splicing
events (Watts and Corey, 2012; Kole
et al., 2012; Saleh et al., 2012).
AONs that achieve gene silencing
by directing mRNA cleavage events arewidely studied and used in both research applications and in
therapeutic development, with several candidates explored in
the clinic. In almost all cases, AONs stimulate mRNA cleavage
through the recruitment of an endogenous endonuclease known
as RNase H. RNase H enzymes, which are involved in essential
steps of the DNA replication process, are known to cleave the
RNA strand of a DNA-RNA duplex (Stein and Hausen, 1969;
Lima et al., 2007; Cerritelli and Crouch, 2009; Bennett and
Swayze, 2010). In humans, the specific enzyme recruited by
AON-mRNA duplexes is RNase H1 (Wu et al., 2004).
The cleavage mechanism through which RNase H mediates
hydrolysis of an internucleotide phosphate linkage in the RNA
strand of a DNA/RNA hybrid duplex is under active investigation,
and relies on divalent metal ion(s) (Mg2+) for catalysis (Ho et al.,
2010; Hollis and Shaban, 2011). A widely accepted mechanism
for RNase H phosphodiester hydrolysis involves a model in
which two highly coordinated metal cations (often described
as ‘‘metal A’’ oriented 30 to the scissile phosphate, and ‘‘metal
B’’ oriented to the 50) are present in the active site, coordinated
by acidic amino acid residues, nonbriding oxygen in the ON
Figure 2. mRNA-Targeting by miRNA and
siRNA
Naturally produced miRNAs, loaded into RISC,
are capable of recognizing and binding partially
complementary mRNAs, especially those with
sequence complementarity to the miRNA ‘‘seed
region.’’ The result is a decrease in gene ex-
pression, adding an additional layer of post-
transcriptional control over gene expression. Anti-
miRNAs can target and inhibit these miRNAs.
As well, synthetic siRNAs, mimicking natural
miRNAs, can be introduced into cells to utilize the
cellular RISC machinery for targeted mRNA gene
silencing.
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Metal A may facilitate activation of water for in-line SN2-like
nucleophilic attack on the internucleotide linkage, with metal B
in position to stabilize the transition state leading to 30-OH and
50-phosphate RNA cleavage products without cleaving the
DNA strand. There is also evidence that a third Mg2+ cation
may be involved in facilitating enzymatic activity, which can
help explain the sensitivity of RNase H activity toward Mg2+
concentration changes (Ho et al., 2010).
Duplex conformation and flexibility in the AON/RNA hybrid is
critical for the stimulation of RNase H activity, and could provide
an explanation for the specificity of RNase H for DNA/RNA hybrid
duplexes, but not dsDNA or dsRNA (Noy et al., 2004, 2005,
2008). Structurally, dsDNA duplexes are B-form, and do not
closely resemble DNA/RNA heteroduplexes. A-form dsRNA is
more similar in conformation to DNA/RNA hybrid duplexes, but
the rigidity of the two strands in dsRNA duplexes may compro-Chemistry & Biology 19, August 24, 2012mise RNase-H function (Mangos et al.,
2003 and references therein).
RNAi-, miRNA-, and siRNA-
Mediated Gene Silencing
The RNAi pathway is an important cellular
process triggered by endogenous nucleic
acids, as a means through which cells
can achieve posttranscriptional gene ex-
pression control through the use of
miRNA expression (Figure 2). RNAi was
discovered following the observation
that dsRNA sharing sequence with a
cellular mRNA (Onc-22) silenced ex-
pression of that gene in Caenorhabditis
elegans (Fire et al., 1998). It was subse-
quently found that RNAi could be trig-
gered in mammalian cells using 21 nt-
long dsRNA duplexes (Elbashir et al.,
2001). The RNAi pathway in the mamma-
lian system is the focus in this overview.
A summary of the RNAi pathway is
shown in Figure 2. The miRNA triggers
of RNAi are typically produced from tran-
scription of intergenic or intronic DNA
regions (Duroux-Richard et al., 2011), to
form primary miRNA (pri-miRNA) hairpins
that are further processed into dsRNA
duplexes featuring a hairpin loop withimperfect sequence complementarity, termed precursor miRNA
(pre-miRNA). Pre-miRNAs are exported out of the nucleus and
processed by an endoribonuclease called Dicer (usually with
an associated dsRNA-binding protein, TRBP) to form mature
miRNA (for reviews, see Filipowicz et al., 2008; Kawamata and
Tomari, 2010; Lennox and Behlke, 2011).
miRNAs, which are 21 nt-long dsRNAs with 2 nt-long 30
overhangs and imperfect complementarity, are recognized and
loaded into a complex of enzymes and proteins known as
the RNA-induced silencing complex (RISC). One of the two
miRNA strands, called the ‘‘guide strand’’ or miRNA strand, is
selected and used in the RISC complex. The other, called the
‘‘passenger strand’’ or miRNA* strand, is discarded. The guide
strand is ‘‘antisense,’’ or complementary, to the sequence of
the targeted mRNA, whereas the passenger strand is ‘‘sense’’
to the mRNA sequence. The RISC complex subsequently finds
cellular mRNAs partially complementary to the loaded guideª2012 Elsevier Ltd All rights reserved 939
Figure 3. hAGO2 with Loaded siRNA
(A) A simplified diagram of AGO2 domains, and their interaction with siRNA.
The MID sub-domain binds the 50P and nucleotide of the guide strand. The
PIWI sub-domain contains the RNase H-like fold with endonucleolytic
cleavage activity, which cuts the siRNA passenger strand during loading, and
the mRNA during gene silencing. The PAZ domain binds the guide strand
30OH.
(B) Classical siRNA structure; 21 nt RNA duplex with 2 nt 30 overhangs. The
antisense strand (‘‘guide’’ strand) is complementary to target mRNA. The
sense strand (‘‘passenger’’ strand) is complementary to the guide strand.
The guide strand contains the seed region at the 50.
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arrest or mRNA cleavage. The extent of sequence complemen-
tarity between the miRNA guide strand and the mRNA target is
thought to determine whether translation arrest (partial comple-
mentarity) or mRNA cleavage (near full complementarity) results
from mRNA recognition by RISC (Humphreys et al., 2005).
Most miRNAs are only partially complementary to their mRNA
targets, thus translational arrest is more common. For the gene
silencing event to occur at all, a short region composed of nucle-
otides 2–8 counting from the 50 end of the guide strand (the
‘‘seed region’’) must recognize a complementary sequence in
the mRNA, usually within the 30 UTR (Humphreys et al., 2005).
From a chemical perspective, miRNAs are essentially short
dsRNA molecules, mimics of which can be readily synthesized.
Small interfering RNAs, or siRNAs (Figure 3), are exogenously
produced double-stranded RNAs, typically 21–24 nt in length
with 2 nt 30 overhangs, designed to mimic miRNAs. siRNAs func-
tion very similarly to miRNAs in gene silencing, and naming
convention with siRNAs is the same, the loaded strand is the
guide and the discarded strand is the passenger. Unlike
miRNAs, siRNAs are designed to share full sequence comple-
mentarity with a single target mRNA.940 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd AllDuring RISC loading with siRNA, one of the two siRNA
strands is loaded into RISC, while the other is cleaved and
unwound from the guide strand to be discarded (Matranga
et al., 2005; Leuschner et al., 2006), although cleavage is not
obligatory (Matranga et al., 2005). In flies, Dicer-2 and R2D2
(an associated dsRNA binding protein) interact with siRNA,
and facilitate this loading into RISC (Kawamata and Tomari,
2010; Betancur and Tomari, 2012). In mammals, RISC loading
is somewhat less understood, and at least in some cases, Dicer
is not required for siRNA loading (Betancur and Tomari, 2012).
The strand selection process in which RISC designates guide
and passenger strands from duplex siRNAs and miRNAs is
based on several factors, including duplex thermodynamics
(where the strand with the least tightly bound 50 end is usually
designated the guide strand; Khvorova et al., 2003; Schwarz
et al., 2003); the presence of a 50 phosphate (that is required
for binding of the guide strand within RISC; Schwarz et al.,
2002); and the sequence at the 50 of the strands (U and A 50
nucleotides may be preferred over G and C for AGO2; Frank
et al., 2010). After loading, siRNA directs gene silencing through
mRNA cleavage and catalytic turnover mediated by a compo-
nent of RISC, an endoribonuclease called Argonaute-2 (AGO2)
(Figures 2 and 3).
A particularly elegant model for siRNA guide strand selection
and RISC loading has recently been proposed, in which dsRNA
is processed in a catalytic region of Dicer to form an siRNA or
miRNA product, which is subsequently released and reposi-
tioned to make contacts with the Dicer helicase domain. Dicer
interacts with the dsRNA on the less stable end of the duplex,
and TRBP (or PACT) on the more stable end, spatially orienting
the duplex for a subsequent AGO2 loading step in which TRBP
(or PACT) may hand off the stable end of the duplex to the
PAZ domain (the guide strand 30-binding domain) of AGO2 (No-
land et al., 2011). This proposed model suggests a mechanism
through which guide strand selection can occur based on siRNA
duplex thermodynamic asymmetry, corresponding to observa-
tions that the siRNA strand with the least tightly bound 50 end
frequently becomes the RISC guide (Khvorova et al., 2003;
Schwarz et al., 2003).
The fate of siRNA passenger strand during RISC loading has
yet to be fully elucidated. Currently, there are three proposed
mechanisms for dealing with the siRNA passenger strand during
loading: (1) the siRNA passenger strand is cleaved by the hAGO2
PIWI subdomain upon loading of the guide strand and released
(Gaynor et al., 2010); (2) a bypass mechanism independent of
passenger strand cleavage exists, in which an ATP-dependent
helicase activity is invoked for passenger strand unwinding (Gay-
nor et al., 2010); and (3) the passenger strand is ‘‘nicked’’ by
hAGO2, triggering C3PO (component 3 promoter of RISC) to
degrade the remaining passenger strand fragments (Ye et al.,
2011). Interfering with passenger strand cleavage through intro-
duction of 20 modifications at the scissile nucleotide position can
significantly impair gene silencing, although not in all cases (Mar-
tinez and Tuschl, 2004; Matranga et al., 2005; Muhonen et al.,
2007). RISC-mediated ON cleavage produces a 30-OH fragment
and a 50-phosphate fragment (Martinez and Tuschl, 2004),
suggesting a free 20 hydroxyl group available to form the 20–30
cyclic phosphate observed for some other nucleases is not
necessary. These observations should be carefully consideredrights reserved
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modified near the hAGO2 cut site.
Clearly, the RISC complex plays a central role in the RNAi
pathway, performing essential functions in RNAi-mediated
gene silencing. Optimizing interactions with RISC may be the
key to improving the potency of siRNA therapeutics. At the
core of the RISC complex lies an endoribonuclease belonging
to the Argonaute (AGO) family, which both anchors the loaded
guide strand from miRNA/siRNA, and performs the key endonu-
clease function of the RISC complex via an RNase H-like fold (Liu
et al., 2004). In humans, the AGO clade of the Argonaute family
has four members: hAGO1, hAGO2, hAGO3, and hAGO4 (Gay-
nor et al., 2010; Gagnon and Corey, 2012). Of these, only
hAGO2 has Slicer-type activity (Meister et al., 2004), and thus
hAGO2 is of particular interest as the core catalytic component
of RNAi gene silencing.
Human AGO2, hAGO2, has four principal domains:
N-terminal, PAZ, MID, and PIWI (see Figure 3) (Jinek and
Doudna, 2009; Gaynor et al., 2010; Gagnon and Corey, 2012).
When an siRNA is loaded into RISC, the guide strand becomes
highly associated with hAGO2. The 30 end of the guide strand
is recognized by the PAZ domain (Ma et al., 2004), and the 50
nucleotide (with an essential 50 phosphate) is anchored in the
MID domain 50 binding pocket (Ma et al., 2005; Frank et al.,
2010). The 50 phosphate can be added synthetically or by an
endogenous kinase (i.e., Clp1) (Weitzer and Martinez, 2007).
The anchoring of the 50 nucleotide to the 50 binding pocket bends
it out and away from the rest of the guide strand, making it
unavailable for the target mRNA base-pairing interactions seen
in the neighboring seed region nucleotides (Frank et al., 2010;
Gaynor et al., 2010). The PIWI subdomain of hAGO2 contains
an RNase H-like activity dependent on two Magnesium ions
(as described above), and catalyzes the mRNA target cleavage
(Liu et al., 2004; Gaynor et al., 2010). The cleavage of the target
RNA, either the siRNA passenger strand, or the mRNA, occurs
between the nucleotides paired to nucleotides 10 and 11 of the
hAGO2 guide strand (measured from the 50 end) (Soutschek
et al., 2004; Kraynack and Baker, 2006; Ui-Tei et al., 2008; Judge
et al., 2009).
Anti-miRNAs and Gene Regulation
As our understanding of the complex roles played by miRNAs
continues to grow, so does the view that a wide range of disease
might be treatable through miRNA targeting (for a good com-
mentary, see Ambros, 2008). We now recognize that miRNAs
play strikingly important functions. Hundreds of miRNAs have
been identified in the human genome, which may be capable
of regulating up to 60% of protein-coding genes (Filipowicz
et al., 2008; Friedman et al., 2009). Because seed-region com-
plementarity is all that is necessary to producemRNAdownregu-
lation, and many different mRNAs can all contain the same short
sequences in their UTRs, a single miRNA sequence is capable
of exerting control over multiple genes. Indeed, miRNAs are
involved in regulating numerous biological processes, ranging
from cell differentiation and development to apoptosis, which
has motivated significant efforts to develop means for exerting
control overmiRNA activity both in vitro and in vivo. Malfunctions
in the miRNA regulation system have been implicated in devel-
opmental changes, metabolism, rheumatoid arthritis (Duroux-
Richard et al., 2011), viral infection, and cancer (SonenbergChemistry & Bioloand Hinnebusch, 2009; Lennox and Behlke, 2011; Bhayani
et al., 2012).
The importance of miRNA gene regulation has attracted a
substantial amount of research into the development of agents
and techniques for exerting control over miRNA function. Fortu-
nately, successes in RNAi and AON research can be readily
applied to miRNA study. Elucidation of the RNAi pathway has
revealed the importance of miRNAs, their structure, and their
production in the cell, and advances in AON design have facili-
tated the development of miRNA-targeting ONs. Termed anti-
miRNA ONs (sometimes called AMOs) (Lennox and Behlke,
2011), the majority of this class of ONs function via a steric block
mechanism, in which miRNA function is inhibited by strong
hybridization with exogenously introduced anti-miRNAs in order
to block RISC loading (Figure 2). Anti-miRNAs may be designed
to trigger miRNA cleavage by RNase H as well, but this has been
less common thus far (Lennox and Behlke, 2011). A typical anti-
miRNA is a perfect complement to themiRNA target (Lennox and
Behlke, 2011), and typically features chemical modifications to
enhance nuclease stability and target binding affinity.
Challenges in the Field
The development of ON therapeutics based on AON, siRNA, and
anti-miRNA platforms have all proven highly potent and effective
in in vitro cell assays. However, as previously mentioned, trans-
lation from the bench to the clinic has been hampered by signif-
icant challenges arising from: (1) the poor in vivo stability of
nucleic acids, (2) ineffective uptake of nucleic acids to target
cells, and (3) the potential for off target effects (OTEs) and immu-
nostimulation. Chemical modifications to native DNA and RNA
structures have gone a long way in abrogating many of these
obstacles, and will be discussed in the subsequent section,
following a brief description of the specific challenges facing
ON therapeutics.
Nuclease Stability
Nucleic acids, RNAs in particular, are rapidly degraded in cells.
AONs, siRNAs, and anti-miRNAs all suffer from these cellular
degradation mechanisms, leading to shortened duration of
activity and systemic delivery challenges. Duplex RNAs, such
as siRNAs, are more nuclease resistant than RNA single strands,
however unmodified siRNAs are also degraded quickly in serum
(Turner et al., 2007). A human ortholog of ERI-1 may be a major
contributor in siRNA degradation (Kennedy et al., 2004). In the
case of siRNAs, it appears that cleavage frequently happens
after pyrimidines (Turner et al., 2007), which could be useful
to consider when designing chemically modified siRNAs. As
discussed below, chemical modification strategies have been
developed to improve the nuclease resistance of ONs, without
altering the nucleic acid sequence.
Effective and Targeted Delivery
Primary approaches being explored for achieving efficient
cellular delivery of therapeutic ONs include both the develop-
ment of ON conjugates (therapeutic ONs are covalently attached
to moieties facilitating cellular uptake), and the development of
delivery vehicles designed to encapsulate and shield ONs, as
well as facilitate and target their cellular uptake. Strategies may
be designed for either local or systemic administration, and
systemic delivery approaches are now being investigated in clin-
ical trials with some success (Yuan et al., 2011). However, thegy 19, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 941
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livery technologies will be welcome additions to the field.
Nucleic acids can benefit tremendously from conjugation
with biologically relevant moieties. There are examples in which
nucleic acid conjugates have demonstrated increased circula-
tion time, improved cellular uptake and endosomal release,
and targeted tissue uptake and cellular localization. For thorough
reviews of ON conjugates, their biological activity, and the
synthetic strategies employed in oligonucleotide conjugate
chemistry, please refer to these excellent reviews: Manoharan
(2002), Lo¨nnberg (2009), and Juliano et al. (2012).
The use of delivery vehicles to transport siRNA has proven
a very promising mode of ON delivery, protecting siRNA from
degradation and increasing cellular uptake. In fact, the first
example of targeted systemic delivery of siRNAs in humans
was recently reported, in which cyclodextrin-based nanopar-
ticles were used to deliver siRNAs to patient tumors, effecting
reduction of target gene mRNA and protein (Davis et al., 2010).
An RNAi mechanism was evidenced by 50-RACE PCR, which
demonstrated that mRNA cleavage occurred precisely at the
predicted AGO2 cleavage site in the mRNA (Davis et al., 2010).
However, delivery vehicles often enter cells via endocytosis,
which can lead to entrapment of siRNAs in endosomes and lyso-
somes rather than achieving their efficient release into the cyto-
plasm (Li and Huang, 2006). Additionally, delivery vehicles often
expose siRNAs to endosomal immune receptors, potentially
leading to undesirable immunostimulatory responses.(White-
head et al., 2011) Again, chemical modification of the siRNAs
themselves may be the only option for abrogating immune
responses. Further discussion of current ON delivery strategies
(including in vivo strategies) can be found in recent reviews
(Yuan et al., 2011; Juliano et al., 2012; Rettig and Behlke, 2012).
OTEs and Immunostimulation
The knockdown of unintended genes (mRNAs) following ON
treatment is a well-known side effect of both siRNA and AON-
mediated gene silencing, although these effects are more
frequently associated with siRNAs. These hybridization-depen-
dent OTEs are generally observed as a result of partial comple-
mentarity between the ON agent and mRNAs other than the
intended target. In the case of siRNAs, OTEs can happen when
the siRNA passenger strand is selected as the RISC guide, or
when the loaded guide strand functions in miRNA fashion,
recognizing targets mainly on the basis of seed region comple-
mentarity, which is a short sequence more likely to be found in
multiple mRNAs (Jackson et al., 2006b). In the case of siRNAs,
two sets of OTEs are possible. Careful sequence selection
when designing siRNAs and AONs, as well as chemical modifi-
cations to reduce the likelihood of siRNA passenger strands
acting as guide strands, can be beneficial for minimizing OTEs
(Deleavey et al., 2009). In addition, chemical modifications of
the siRNA seed region can be used to reduce OTEs (Jackson
et al., 2006a). In the case of anti-miRNAs, sequence selection
is limited due to the inherent small size of the miRNA target,
which could be problematic when targeting one miRNA from
a family with significant sequence homology. Microarray tech-
nology can be used to monitor changes in cellular gene expres-
sion following oligonucleotide treatment (Jackson et al., 2003).
Immunostimulation following ON treatment is another poten-
tial side effect that is of concern in the development of ON ther-942 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd Allapeutics (Marques and Williams, 2005; Watts et al., 2008a), and
can confuse experiments designed to measure gene silencing
potencies of AONs and siRNAs (Marques and Williams, 2005;
Kleinman et al., 2008). For example, the nonspecific innate
immune responses triggered by siRNAs and AONs can cause
changes in cellular gene expression levels, affecting gene
silencing data and antiviral activity measurements, and can
lead to phenotypic changes such as reduced tumor angiogen-
esis (Kleinman et al., 2008). Immune system responses to short
nucleic acids such as siRNAs is a complex topic, and has
been reviewed in detail elsewhere (Whitehead et al., 2011).
For the purposes of this review, it should be noted that dif-
ferent cellular immune receptors, positioned in different cellular
locations, detect AONs and siRNAs, potentially leading to cyto-
kine release and changes in gene expression. siRNA receptors
include TLR3 (dsRNA, cell surface, and endosomal), TLR7
(ssRNA, endosomal), TLR8 (ssRNA, endosomal), MDA5 (cyto-
plasm), RIG-I (cytoplasm), and PKR (cytoplasm).(Takeda and
Akira, 2005; Judge and MacLachlan, 2008; Kleinman et al.,
2008; Watts et al., 2008a; Zamanian-Daryoush et al., 2008; Del-
eavey et al., 2009; Whitehead et al., 2011) AONs can be immu-
nostimulatory as well. For example, when DNA sequences
such as AONs contain unmodified 50-CpG motif(s), they can
be immunostimulatory upon recognition by TLR9 (endosomal)
(Hemmi et al., 2000; Krieg, 2012). Immunostimulatory sequence
motifs have also been identified for siRNAs, such as the 50-UGU
GUU (Judge et al., 2005) and 50-GUCCUUCAA motifs (Hornung
et al., 2005). In addition, it should be noted that the type of
delivery vehicle used will influence the mode of cellular uptake,
which can determine the number and type of immune receptors
to which the oligonucleotides can be exposed (Whitehead et al.,
2011). Many of the chemical modifications described below can
dramatically reduce the immunostimulatory properties of nucleic
acids, providing an effective means for avoiding these potential
side effects. It should be noted that abrogating immunostimula-
tion is not always beneficial, as in the cases of isRNAs (Schlee
et al., 2006) and oligonucleotide adjuvants (Klinman, 2004), but
in siRNAs, AONs, and anti-miRNAs, minimizing immunostimula-
tion is often desired. Discussion of immunostimulatory oligonu-
cleotides can be found elsewhere (Barchet et al., 2008; White-
head et al., 2011).
Chemical Modifications of ONs
The continued development of chemically modified nucleoside
analogs has provided nucleic acid chemists with the tools
necessary to exert a remarkable amount of control over many
important nucleic acid properties, including: binding affinity for
RNA targets, structural preferences, nuclease stability, and im-
munostimulatory properties. An exhaustive list of all nucleic
acid chemical modifications is beyond the scope of this review;
however, this section will discuss many of the frequently utilized
chemical modifications, as well as some interesting recent addi-
tions, keeping in mind the biological pathways and nucleic acid
characteristics already described.
Generally speaking, chemical modifications of nucleic acids
can be classified into three distinct categories: (1) internucleotide
linkage modifications, (2) sugar modifications, and (3) nucleo-
base modifications. Below we elaborate on each of these cate-
gories.rights reserved
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Figure 4. Selected Chemical Modifications of Internucleotide Linkages
Phosphodiester linkages form the backbone of natural DNA and RNA. Minor chemical modification of this chemical functionality can impart significant changes
with respect to nuclease resistance, biological activity, duplex thermal stability, and cellular uptake. In some cases, significant departure from natural structure
can be advantageous as well (e.g., Morpholino, peptide nucleic acid). X = H (DNA) or OH (RNA). Note: Some modifications have only been reported for only
deoxyribose or ribose sugars, and not both.
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The internucleotide phosphodiester linkages of DNA and RNA
are negatively charged at physiological pH (pKa 2), and can
be readily cleaved by endo- and exonucleases found in serum
and within mammalian cells. Chemical modifications of these
bonds have been extensively studied, and several chemical
strategies have proven very successful for improving nuclease
resistance, some of which are still compatible with an RNase-
H-mediatedmRNA cleavagemechanism, and a few impart addi-
tional beneficial characteristics to ONs. Internucleotide linkage
modifications are often combined with sugar modifications,
allowing for additional control over ON properties. Figure 4 pres-
ents some of the frequently used internucleotide linkage modifi-
cations, and this section will briefly describe some of the features
imparted by these design strategies.
The phosphorothioate (PS) linkage, where sulfur substitutes
for one nonbridging phosphate oxygen (Eckstein, 1966, 1967,
2000), imparts significant resistance to nuclease degradation,
and is widely used in AON applications. PS linkages are cost-
effective modifications, readily incorporated using standard
solid-phase ON synthesis protocols (Sanghvi, 2011). PS modifi-
cation is a major component of first generation antisense thera-
peutic candidates (Sanghvi, 2011; Bennett and Swayze, 2010),
and although some toxicity has been observed, PS modifi-
cations are found in a FDA-approved ON drug, Formivirsen
(Sanghvi, 2011). Although the PS modification can reduce
the binding affinity for a complementary strand (Kibler-Herzog
et al., 1991; Milligan et al., 1993), this modification is still very
compatible with RNase H-mediated mRNA cleavage (Agrawal
and Kandimalla, 2000). The PS linkage introduces chirality to
internucleotide linkages, and one stereochemistry (Sp linkage)
is highly resistant to nuclease-mediated cleavage (Eckstein,
2002). Strategies for diastereoselective synthesis of PS linkagesChemistry & Biolohave been described (Guga and Stec, 2003). It is common to
synthesize PS-modified AONs as a diastereomeric mixture,
because each AON will contain multiple resistant linkages, and
the overall stability of the population is enhanced. PS linkages
in nucleic acids can also enhance their affinity for binding with
serum albumin (Bennett and Swayze, 2010), which can improve
pharmacokinetics and circulation time. PS-modified AONs can
also be taken up by cells without the use of transfection or elec-
troporation (Stein et al., 2010). PS linkages have also been incor-
porated into siRNAs without significant loss of potency, but can
reduce activity in some cases (Deleavey et al., 2009), including
modifications at the AGO2 cleavage site (Leuschner et al., 2006).
N30 phosphoramidate (NP) linkages replace 30-OH groups
for 30-amine functionality (Chen et al., 1995). NP modifications
adopt a North sugar conformation, making them suitable mimics
for RNA substitution (Gryaznov, 2010). As a result, NP containing
ONs lack the ability to activate RNase-H-mediated cleavage
(Heidenreich et al., 1997), but feature good binding affinity for
target sequences and high nuclease resistance. Indeed, NP
oligonucleotides can serve as potent RNase H-independent
antisense oligonucleotides. Target-binding affinity can be further
enhanced by combining 20-OH or 20-F functionality with NP-
modified sugars (Gryaznov, 2010). These linkages can substitute
a sulfur for a nonbridging oxygen in the internucleotide linkage as
well, mimicking the PS linkage modification in some ways (for
example, internucleotide linkages become chiral upon substitu-
tion with sulfur), while retaining enhanced binding affinity (Gryaz-
nov, 2010).
Boranophosphate internucleotide linkages also impart chi-
rality, and can be incorporated in siRNAs, with the resulting
constructs being capable of triggering potent gene silencing
(Hall et al., 2004). These modifications, not unlike PSs, impart
improved nuclease stability as well. Boranophosphate-modifiedgy 19, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 943
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cleavage mechanism of action (Rait and Shaw, 1999).
Phosphonoacetate (PACE) linkages substitute an acetic acid
group for a nonbridging oxygen in the internucleotide linkage,
again introducing chirality to the linkage. PACE modifications
retain the negative charge character of unmodified DNA (PACE
pKa3.8), demonstrate enhanced nuclease resistance (Dellinger
et al., 2003; Sheehan et al., 2003), and adopt A-form duplexes
when bound to RNA targets (Sheehan et al., 2003). PACE ONs
are able to activate RNase H activity (Dellinger et al., 2003; Shee-
han et al., 2003). PACE modification slightly reduces binding
affinity for RNA complement strands (1.3C per insert for
an RNA target in high salt conditions) (Sheehan et al., 2003).
Interestingly, neutral esters of PACE ONs can be taken up by
cells unassisted, perhaps allowing cellular esterases to subse-
quently release anionic acetate ONs inside cells, in a ‘‘pro-
drug’’ approach to ON delivery (Sheehan et al., 2003; Yamada
et al., 2007). Although de-esterification does not produce natural
phosphodiester linkages, these modified ONs retain the ability
to trigger RNase H.
The nonbridging oxygen can also be replaced by sulfur
to produce thio-PACE, which shares many of the qualities
observed for PACE modifications (Sheehan et al., 2003). 20-O-
Me versions of PACE and thio-PACE ONs have recently been
synthesized and tested in siRNA and anti-miRNA constructs as
well (Threlfall et al., 2012). Modification of RNA with 20-O-Me
PACE was stabilizing relative to an RNA-RNA duplex in most
cases, and 20-O-Me thio-PACE was only slightly destabilizing.
Both modifications were tolerated in siRNA constructs, with
the 20-O-Me thio-PACE demonstrating a slight advantage over
20-O-Me PACEmodifications. With lipid transfection, both modi-
fications performed slightly worse than unmodified siRNA, but
were able to effect some gene silencing in the absence of
transfecting agent, indicating some unassisted uptake of siRNA
duplexes with modified passenger strands. Single stranded 20-
O-Me thio-PACE ONs were effective at unassisted cell uptake,
and notably improved the potency of a 20-O-Me-based anti-
miRNA targeting miRNA-122 in the absence of lipid transfection
(Threlfall et al., 2012).
Morpholino phosphoramidates are uncharged substitutes of
the internucleotide phosphodiester linkages and the furanose
sugars of nucleic acids. These modified ONs can have similar
or even improved binding affinity for target strands (Summerton,
1999; Corey and Abrams, 2001; Du and Gatti, 2011), and can be
used as translational inhibitors (Bennett and Swayze, 2010) and
anti-miRNAs (Bennett and Swayze, 2010). Although morpholino
phosphoramidates lack the ability to trigger RNase H (Summer-
ton and Weller, 1997), they have proven resistant to nuclease
degradation (Summerton and Weller, 1997). Morpholino ONs
have proven particularly successful as RNase H-independent
AONs and anti-miRNAs in Zebrafish systems for conducting
functional genomics studies (Lennox and Behlke, 2011), and as
pre-mRNA splicing modulators (Du and Gatti, 2011; Kole et al.,
2012).
Peptide nucleic acid (PNA) has a neutral charge backbone
composed ofN-(2-aminoethyl)glycine, exhibits significant nucle-
ase and protease resistance (Demidov et al., 1994), binds ONs
with higher affinity than DNA or RNA (Shakeel et al., 2006), obeys
base pairing rules (Egholm et al., 1993), and features a number of944 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd Allinteresting properties. PNAs do not activate RNase H, and
can act via a translational inhibition mechanism (Bennett and
Swayze, 2010), in siRNA overhangs (Potenza et al., 2008),
and in numerous other biological pathways including splice-
switching activities (Nielsen, 2010). PNA is also particularly use-
ful in anti-miRNA applications. PNA has an interesting dsDNA
invasion property (Peffer et al., 1993; Nielsen, 2010), in which it
can invade dsDNA to form a variety of complex PNA/DNA struc-
tures (Nielsen, 2010). The structure of PNA is a major departure
from typical nucleic acid structure, substituting both the inter-
nucleotide linkages and sugars for a peptide-based backbone.
The nucleobases, however, can remain unchanged, and target
recognition occurs via base pairing (mainly base stacking) (Niel-
sen, 2010) in either antiparallel or parallel orientations (Peffer
et al., 1993; Nielsen, 2010). Since the discovery of PNA (Nielsen
et al., 1991), awide variety of PNA analogs have been developed,
and are reviewed elsewhere (Pensato et al., 2007).
Sugar Modifications
Chemically modified sugars provide a remarkable level of
control over nucleotide sugar puckering preferences, which is
a physical property intimately related to ON binding affinity
toward complementary strands, duplex conformation, and, by
extension, quality of enzyme interactions. Sugar conformation
can be altered through manipulation of gauche and anomeric
effects, or via steric restraints. The conformation of sugar rings
is readily described using phase angle values, calculated from
the dihedral angles of the furanose rings. In turn, these phase
angle values can be represented on a so-called ‘‘pseudorota-
tional wheel’’ that provides an intuitive means for describ-
ing nucleotide sugar ‘‘puckering’’ or conformation (Altona and
Sundaralingam, 1972; Blackburn et al., 2006) Most nucleotide
sugars and analogs adopt conformations characterized on the
pseudorotational wheel as either ‘‘North’’ (C30-endo, C20-exo),
or ‘‘South’’ (C20-endo, C30-exo), passing through the ‘‘East’’
(O40-endo) when moving between these conformational minima
(Figure 5). In B-form, dsDNA sugars adopt the ‘‘South’’ puck-
ering, whereas in A-form dsRNA sugars prefer the ‘‘North’’
conformation. These structural considerations can be particu-
larly important when considering chemical modification strate-
gies for gene silencing ONs, and will be discussed for the sugar
modifications presented in this section. The cellular enzymes
involved in both siRNA- and AON-mediated gene silencing are
tolerant toward several chemically modified sugars, some of
which are highlighted in Figure 6 and described below.
The 20-O-Me nucleoside analog is one of the most widely used
modifications. Compared with a DNA strand, incorporation of
20-O-Me units within ONs increases binding affinity for RNA
complements (Majlessi et al., 1998), and increases nuclease
stability (Rettig and Behlke, 2012). 20-O-Me sugars prefer a North
sugar conformation (Kawai et al., 1992; Nishizaki et al., 1997),
resembling RNA, and form A-form duplexes (Nishizaki et al.,
1997). This means that these units are particularly well suited
for siRNA modification. Indeed, 20-O-Me units are well tolerated
in siRNAs, although in at least some situations extensive modifi-
cation should be avoided (Czauderna et al., 2003; Deleavey
et al., 2009). 20-O-Memodification has been shown to reduce im-
munostimulatory properties of siRNAs (Whitehead et al., 2011),
which is an attractive feature because innate immune response
side effects have become increasingly concerning in recentrights reserved
Figure 5. The Pseudorotational Wheel and Corresponding Sugar
Pucker Notations
Based on the calculated phase angle (P), nucleoside conformations can be
readily classified. For example, A-form RNA sugars are ‘‘North’’ or C30-endo,
and B-form DNA sugars are ‘‘South’’ or C20-endo. X = H (DNA), X = OH (RNA).
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been widely applied in AON research, especially when incorpo-
rated in so-called ‘‘gapmer’’ AON constructs (described below).
20-O-Me modified ONs are in clinical trials (Sanghvi, 2011), and
can be found in the first FDA-approved aptamer, Macugen (Ng
et al., 2006).
The 20F-RNA modification is another popular chemical modi-
fication in gene silencing/anti-miRNA research. 20F-RNA, like
20-O-Me, is an RNA mimic, preferentially adopting a North sugar
pucker (Ikeda et al., 1998 and contained references), at least
partly due to the strong gauche effect imparted by the 20-fluorine.
Much like 20-O-Me, 20F-RNA increases binding affinity for target
RNA sequences (2C–3C per insert versus DNA) (Kawasaki
et al., 1993; Viazovkina et al., 2002; Bennett and Swayze,
2010), which may be partly due to conformational preorganiza-
tion of the sugar for formation of A-form duplexes, but perhaps
more importantly, due to enthalpy benefits from enhanced
base-pairing and stacking interactions arising from the electro-
negative fluorine (Pallan et al., 2011). 20F-RNA modification is
very well tolerated in siRNA, in both the guide and passenger
strands (Watts et al., 2008a; Deleavey et al., 2009). Phospho-
diester 20F-RNA ONs do not demonstrate significant resistance
to exonucleases (Manoharan, 1999), although 20F-RNA imparts
resistance to pyrimidine-rich sequences toward endonuclease
degradation. 20F-RNA can also modulate splicing upon pre-
mRNA binding through recruitment of the interleukin enhancer-
binding factor 2 and 3 complex (ILF2/3), something not observed
with 20-O-MOE or 20F-ANA (Rigo et al., 2012). The 20F-RNA
modification very closely mimics RNA, making it a versatileChemistry & Bioloand well-tolerated chemical modification for many applications.
Like 20-O-Me, 20F-RNA modifications can also be found in the
FDA-approved aptamer, Macugen (Ng et al., 2006).
The 20-deoxy-20-fluoro-b-D-arabino nucleic acid (20F-ANA)
modification is an epimer of 20F-RNA, structurally identical to
20F-RNA in all respects with the single exception of the fluorine
atom substitution at the 20 position, which corresponds to the
furanose form of arabinose rather than ribose. As a result, 20F-
ANA is a structural mimic of DNA rather than RNA, preferentially
adopting a South/East sugar pucker (Trempe et al., 2001, Berger
et al., 1998; Ikeda et al., 1998). 20F-ANA enhances binding to
RNA complements (1.2C) (Damha et al., 1998; Wilds and
Damha, 2000), enhances nuclease stability in both AON (Kalota
et al., 2006; Watts et al., 2009) and siRNA constructs (Dowler
et al., 2006; Deleavey et al., 2010), and is fully compatible with
RNase H activation for target mRNA cleavage (Damha et al.,
1998). 20F-ANA modification of AONs in gapmer or ‘‘altimer’’
constructs (see below) have beneficial effects on target binding
stability, nuclease resistance, cellular uptake, level of RNA target
degradation, duration of activity, and potency (Min et al., 2002;
Kalota et al., 2006; Watts and Damha, 2008). Perhaps somewhat
surprisingly, 20F-ANA (a DNA-like modification) is also compat-
ible with siRNA chemical modification, especially in the pas-
senger strand (Dowler et al., 2006; Deleavey et al., 2010). In addi-
tion, combining 20F-ANA with RNA-like chemical modifications
(LNA, 20F-RNA) can produce fully modified siRNAs with en-
hanced gene silencing potency, increased nuclease stability,
and significantly reduced immunostimulatory properties (Delea-
vey et al., 2010). Chimeric siRNAs fully modified with 20F-ANA
and 20F-RNA can maintain or improve siRNA potency, and can
be designed to introduce thermodynamic asymmetry in siRNA
duplexes (Deleavey et al., 2010). Perhaps because 20F-ANA is
an excellent siRNA passenger strand modification, these chem-
ical modifications likely have poor potency in anti-miRNA appli-
cations. 20F-ANA-modified PS AONs are compatible with gym-
notic delivery techniques for achieving gene silencing without
transfection, which has already been observed with PS LNA-
DNA AONs (Stein et al., 2010). The improved thermal stability
of 20F-ANA-RNA duplexes are partly due to pseudohydrogen
bonding between the 20-fluorine and purine H8 (Watts et al.,
2010; Anzahaee et al., 2011), an observation that can be ratio-
nally applied to AON design (Anzahaee et al., 2011). A related
nucleoside analog, the RNA-like 40S-FANA, is also compatible
with siRNA-mediated gene silencing (Watts et al., 2007).
Locked nucleic acid (LNA) is a chemically modified RNA
analog featuring a methylene bridge joining the 20-OH to the
C40, essentially forming a conformationally restricted bicyclic
nucleoside (Koshkin et al., 1998; Obika et al., 1998). These nucle-
oside analogs are essentially locked in a North sugar conforma-
tion that closely mimics A-form RNA, preorganizing LNAs for
RNA-binding (Koshkin et al., 1998; Obika et al., 1998; Braasch
and Corey, 2001). LNA units impart the most impressive duplex
stability effects of the available chemical modifications, with
stabilizations of 5.6C per insert (Koshkin et al., 1998). As a
result, LNAs have proven very useful in anti-miRNA (Lennox
and Behlke, 2011), AON (Braasch and Corey, 2001), and siRNA
(Braasch et al., 2003; Elme´n et al., 2005; Hornung et al., 2005;
Bramsen et al., 2007; Mook et al., 2007; Deleavey et al., 2009)
applications. The strong binding properties of LNA make themgy 19, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 945
Figure 6. Selected Chemical Modifications of Oligonucleotide Sugars
A wide variety of chemical modifications have been developed and applied in the design of AONs, siRNAs, and anti-miRNAs. The majority of chemical modi-
fications involve modification of the 20 position of RNA. Other modifications include replacement of the ring oxygen with sulfur (40S-RNA, 40S-FANA); bridges
between the C20 and C40 positions; modified C40 nucleotides, and replacement of furanose with bicyclic, tricyclic, or expanded ring systems.
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sequences can be necessary for miRNA specificity, and LNAs
are excellent AON modifications when used in gapmer con-
structs (Wahlestedt et al., 2000). LNA modifications are also
compatible with siRNA chemical modification (Braasch et al.,
2003; Elme´n et al., 2005; Hornung et al., 2005; Bramsen et al.,
2007; Mook et al., 2007). LNAs have contributed to the develop-
ment of sisiRNAs, which are siRNAswith nicked sense strands to
reduce sense strand-dependent OTEs (Bramsen et al., 2007). In
addition, LNA modification improves nuclease resistance (Wah-
lestedt et al., 2000), and can reduce siRNA immunostimulation
(Whitehead et al., 2011).
Contrasting the rigid nature of the LNAmodification, the highly
flexible unlocked nucleic acid (UNA) (or ‘‘seconucleoside’’) modi-
fication is also being developed for application in ON therapeu-
tics. UNA, missing the covalent C20-C30 bond of a ribose sugar,
is not conformationally restrained, and can be used to influence
ON flexibility (Mangos et al., 2003). UNA inserts can reduce
duplex Tm by 5
C–10C per insert in some cases (Mangos
et al., 2003; Campbell and Wengel, 2011), can facilitate anti-
sense strand selection as the RISC guide, and UNA modifica-
tions to the seed region of an siRNA guide strand can signifi-
cantly reduce OTEs (Vaish et al., 2011). UNA has also been
used in 20F-ANA modified AONs, in efforts to increase duplex
flexibility to accommodate RNase H (Mangos et al., 2003). In
fact, 20F-ANA modified AONs with acyclic residues (UNA and946 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd Allbutyl linkers) amplify RNase H-catalyzed target RNA degra-
dation, suggesting the added flexibility imparted to the sub-
strate structure can enhance the protein/nucleic acid interaction.
Biophysical studies revealed that the enhanced flexibility associ-
ated with a particular UNA modification remain globally unde-
tectable, indicating the acyclic residues induce only local struc-
tural deformations to the hybrid architecture (Mangos et al.,
2003).
The LNA modification is a member of a larger family of nucle-
oside analogs referred to as bicyclic nucleic acids (BNAs). Exten-
sive research has been done on the development of several BNA
nucleosides (Prakash, 2011), only a few of which are shown in
Figure 6. Some of the examples of BNAs that have been applied
in AON research includemethylene carbocyclic LNA (methylene-
cLNA) (Seth et al., 2010), N-MeO-amino BNA, N-Me-aminooxy
BNA, and 20,40-BNANC[NMe] (Prakash et al., 2010). Bicyclo
[3.1.0]hexane-based nucleoside analogs (20-deoxy-methano-
carba nucleosides [MC]) adopt a North sugar conformation, en-
hance thermal stability of duplexes, and enhance siRNA serum
stability (Marquez et al., 1996; Terrazas et al., 2011). A conforma-
tionally constrained nucleoside analog, tricyclo-DNA (tc-DNA),
has also been developed and tested (Renneberg et al., 2002; Ittig
et al., 2010), based on a tricyclic (rather than bicyclic) structure.
tc-DNA has enhanced binding affinity for RNA, does not activate
RNase H, and is stable to nucleases (Renneberg et al., 2002; Ittig
et al., 2010).rights reserved
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used in several therapeutic candidates undergoing clinical trials
(Bennett and Swayze, 2010). These chemical modifications fea-
ture a methoxyethyl modification at the RNA 20-OH, which
increases target binding affinity (2C per insert) (Manoharan,
1999; Viazovkina et al., 2002), and improves nuclease stability
(comparable with phosphorothioate modification) (Manoharan,
1999). 20-O-MOE modifications adopt a North sugar confor-
mation preorganized for RNA binding, which is also stabilized
by hydration effects (Manoharan, 1999; Bennett and Swayze,
2010). 20-O-MOE groups have been successfully applied to
AON constructs (RNase H compatible when used in gapmer
designs, Manoharan, 1999), and in siRNA, especially in sense
strands (Prakash et al., 2005). One highly promising clinical
candidate successfully advancing in clinical trials, Mipomersen,
is a second generation AON containing PS linkages and 20-O-
MOE sugars (Kole et al., 2012; Kastelein et al., 2006). A number
of similar 20 modifications have been developed for use as gene
silencing agents, including the 20-O-Allyl (Amarzguioui et al.,
2003; Odadzic et al., 2008), 20-O-Ethylamine (Odadzic et al.,
2008; Bramsen et al., 2009), 20-O-Cyanoethyl modifications (Sa-
neyoshi et al., 2005; Bramsen et al., 2009), and 20-O-acetalester
(Martin et al., 2009). Another North-type sugar modification, 20-
azido modified RNA, has also been used for siRNA modification
(Aigner et al., 2011; Fauster et al., 2012).
Although the majority of sugar analog alterations are localized
to the 20 position, many other sites are amenable to modifica-
tion, including the 40 position, as evidenced by modified nucleo-
sides such as 40S-RNA and 40-C-aminomethyl-20-O-Me RNA.
40S-RNA enhances nuclease stability (Leydier et al., 1995; Dande
et al., 2006), has been applied to siRNA chemical modification
(Dande et al., 2006), and is compatible with RISC-mediated
gene silencing. Selenium modification of the 40 position (40Se-
RNA) provides significant stabilization to RNA/RNA and RNA/
DNAhybrid duplexes (Watts et al., 2008b). Other 40 modifications
have been developed, including 40-C-aminomethyl-20-O-Me
RNA, which features modified 40 functionality external to the
5-membered ring (Gore et al., 2012). 40-C-aminomethyl-20-O-
Me RNA is slightly destabilizing versus RNA, stabilizes siRNA
toward nuclease degradation, and does not significantly alter
gene silencing potency (Gore et al., 2012).
It is becoming increasingly clear that the pool of available
modified nucleosides for therapeutic ON analog development
is not limited to 5-membered ring mimics of ribose. In fact, a
number of expanded ring systems have been developed and
applied in gene silencing applications. We have already dis-
cussed morpholino chemistry, which could be considered an
expanded ring ON analog. In addition, cyclohexene nucleic
acid (CeNA) (Verbeure et al., 2001; Nauwelaerts et al., 2007),
altritol nucleic acid (ANA) (Fisher et al., 2007, 2009), oxepane
NAs (ONA) (Sabatino and Damha, 2007), and hexitol NA (HNA)
(Fisher et al., 2009) modifications have all been used in gene
silencing experiments. CeNA binds RNA more tightly than
a DNA strand, increases serum stability, and can activate RNase
H (Wang et al., 2000b; Verbeure et al., 2001). ANA favors A-form
duplex formation due to conformational preorganization, making
it a stable RNA-binding modification. Oxepane nucleic acids
(ONA) are also expanded ring modifications, which are nuclease
resistant and can trigger RNase H (Sabatino and Damha, 2007).Chemistry & BioloNucleobase Modifications
Chemically modified nucleobases have also found application in
ON analog development. Although perhaps less common than
sugar and backbone modifications, modified nucleobases are
numerous, and can be used to affect thermal stability, reduce
immunostimulation, and affect siRNA OTEs. A comprehensive
review of nucleobase modifications can be found elsewhere
(Herdewijn, 2000), inwhich nucleobasemodifications and effects
onRNA-binding are discussed. Aswell, the reader is directed to a
thorough review of nucleobase modifications in siRNA (Peacock
et al., 2011). Nucleobase modifications in PNA have also been
reviewed (Wojciechowski and Hudson, 2007; Nielsen, 2010), as
well as fluorescent nucleobase analogs (Dodd and Hudson,
2009). Here we only provide some brief highlights.
A popular goal in modified nucleobase design is to achieve in-
creased duplex stability while maintaining and improving native
base pairing recognition and hydrogen bonding. The 5-bromo-
Ura and 5-iodo-Ura substitutes of Ura, as well as 2,6-diamino-
purine in place of Ade, are excellent examples of this strategy,
and can be used to stabilize A-U base pairs in ON duplexes
(Chiu and Rana, 2003; Watts et al., 2008a; Deleavey et al.,
2009). C-5 propynyl pyrimidine base modifications also increase
duplex thermal stability, and are compatible with RNase H-medi-
ated gene silencing, but have shown some associated toxicity
(Herdewijn, 2000; Shen et al., 2003; Bennett and Swayze,
2010). In contrast to these modifications, other examples of
modified nucleobases (i.e., difluorotoluene, difluorobenzene, di-
chlorobenzene) lacking oxygen, nitrogen, or classical hydrogen
bond donating groups, have been reported to be beneficial in
siRNA modification (Xia et al., 2006; Somoza et al., 2008; Adde-
palli et al., 2010). Naturally occurring modified nucleobases have
also been used to chemically modify siRNA (2-thiouridine, pseu-
douridine, and dihydrouridine) (Sipa et al., 2007). Generally
speaking, nucleobase modifications can provide a means for
probing and altering duplex thermal stability, sugar conforma-
tion, and nucleobase hydrogen-bonding and steric interactions
(Peacock et al., 2011).
In addition, intrinsically fluorescent modified nucleobases
can be exceptionally useful in studying siRNAs, AONs, and
anti-miRNAs due to their ability to impart fluorescent properties
to nucleic acids. Fluorescent nucleobases can be ‘‘base dis-
criminating,’’ and have been used in a variety of nucleic acid
studies (Dodd and Hudson, 2009). 6-phenylpyrrolocytidine
(phpC) RNA (Wahba et al., 2010, 2011) is an interesting nucleo-
basemodification, which has allowed development of enzymatic
assays for RNase H-mediated cleavage (Wahba et al., 2010)
and detection of siRNA cellular uptake (Wahba et al., 2011).
Finally, a modified nucleobase (N2-alkyl 8-oxoguanosine) can
be used as a ‘‘switch’’ to control steric effects in duplex major
and minor grooves, modulating siRNA interactions with off-
target proteins, while retaining gene silencing potency (Kannan
et al., 2011).
A variety of modified nucleobases with minor-groove projec-
tions can be used to abrogate immunostimulatory responses
to siRNAs and miRNA mimics, perhaps by preventing interac-
tions with TLR and PKR receptors (Peacock et al., 2011). Addi-
tionally, AON immunostimulation responses to CpG motifs can
be abrogated by substitution with 5-methyl cytosine (Krieg,
2012).gy 19, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 947
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AON Design Strategies
In order to improve activity and therapeutic potential of
AON sequences, many chemical modifications discussed above
have been designed and applied to the AON gene silencing
approach. For example, PS-modified AONs can be considered
as 1st generation AON technology, which has produced at least
one successful therapeutic (Fomivirsen) (Sanghvi, 2011). The
second and third generations of AON strategies, building upon
the first generation, utilize additional chemical modifications
(mainly sugar modifications) to further improve therapeutic
potential. Second and third generation AONs typically contain
20-MOE, LNA, 20-O-Me, 20F-ANA, or 20F-RNA sugar modifi-
cations, and are designed to improve potency, mRNA target
binding, nuclease stability, and to reduce immunostimulation.
In order to maintain potency in cases where RNase H-medi-
ated mRNA cleavage is desired, it is generally considered a
requirement that modified AONs retain a polyanionic character
(Sheehan et al., 2003). As well, because RNase H recognizes
DNA/RNA hybrids that tend to adopt conformations intermediate
between A- and B-form, AON-based therapeutics aiming to elicit
target mRNA degradation should retain a continuous region of
DNA or DNA-likemodification in order to ensure RNaseH recruit-
ment and cleavage. The second and third generation sugar
modifications are often implemented in a ‘‘gapmer’’ design, in
which sugar modified nucleotides are on the ON termini, flanking
a central DNA core. This strategy works very well with 20-MOE,
LNA, 20-O-Me, 20F-ANA, or 20F-RNA sugar modifications, and
allows high-affinity RNA-like modifications to be used without
interfering with RNase H activity. In the case of 20F-ANA, a
DNA-like chemical modification, an ‘‘altimer’’ design strategy
can also be employed to activate RNase H, in which 20F-ANA
and DNA regions are alternated every 3 nucleotides (Min et al.,
2002; Kalota et al., 2006).
Anti-miRNA Design Strategies
In general, anti-miRNAs are designed to act as steric blocks,
strongly binding with a miRNA target so as to prevent RISC
loading and mRNA targeting. Anti-miRNAs designed to trigger
RNase H upon miRNA binding have also been tested, but steric
block anti-miRNAs have been somewhat more common and
successful thus far (Lennox and Behlke, 2011). A typical anti-
miRNA is a perfect complement to the miRNA target (Lennox
and Behlke, 2011), and can be designed to tightly bind the entire
miRNA, especially at the seed region of the miRNA, which is
the region critical for miRNA-mediated gene silencing. In fact,
binding affinity to the 50 end of a miRNA target at the seed region
has been shown to influence anti-miRNA specificity and activity
(Davis et al., 2006; Threlfall et al., 2012).
Overall, anti-miRNAs have many similarities to AONs, and
have been developed using many of the same chemical modifi-
cations utilized for AON modification. Some of the most widely
used anti-miRNA modifications are locked nucleic acid (LNA),
20F-RNA, 20O-Me, peptide nucleic acid (PNA), and morpholinos
(Lennox and Behlke, 2011), all of which are described above. An-
tagomirs, which are 20O-Me ONs containing phosphorothioate
linkages and a conjugated cholesterol moiety (Kru¨tzfeldt et al.,
2005, 2007) have also become a successful strategy for target-
ing miRNAs (Kru¨tzfeldt et al., 2005), and can be considered an
addition to the anti-miRNA family.948 Chemistry & Biology 19, August 24, 2012 ª2012 Elsevier Ltd AllIn the case of anti-miRNAs, the cellular RNA target is a
comparatively short miRNA sequence, significantly limiting the
target binding region compared to mRNA targeting AONs and
siRNAs. Short anti-miRNA constructs are desirable, particularly
those with very high binding affinity for the miRNA target. Thus,
LNA has proven a very attractive chemical modification in the
design of anti-miRNAs, owing to its highly stabilizing effect in
RNA hybridization. A correlation between the thermal stability
of binding with the target and overall potency is generally ob-
served, although not predictive in all cases (Lennox and Behlke,
2011), and so target-binding affinity should not be the only
consideration in the design of anti-miRNAs. It has been hypoth-
esized that there is a threshold stability that must be reached for
good potency, after which further affinity increases have less
impact on potency (Lennox and Behlke, 2011).
When an anti-miRNA binds a miRNA target, the result is
an unfolded miRNA annealed to an anti-miRNA ON, which in
some ways could resemble the structure of an siRNA duplex.
Of course, siRNAs are capable of interaction with the RISC
complex and performing gene knockdown, and so care should
be taken when designing anti-miRNAs. More specifically, it has
been shown that chemically modified ONs that are functional
as siRNA passenger strands are low potency anti-miRNAs,
whereasONchemistries detrimental in siRNA passenger strands
can be highly active anti-miRNAs (Davis et al., 2006).
siRNA Design Strategies
The double-stranded nature of this class of gene silencing ONs
makes siRNA design more complex in some respects compared
with AONs and anti-miRNAs. Because the two strands serve
very different functions, chemical modification of siRNAs must
carefully consider which strands are modified and in what
fashion. Additionally, siRNAs can be generated from longer
RNAs by upstream cellular enzymes, in much the same way
that miRNAs are generated. Therefore, RNAi-mediated gene
silencing can be triggered using a variety of longer RNA mole-
cules, including hairpins (termed shRNAs, often produced from
expression vectors, and reviewed elsewhere; Rao et al., 2009),
longer dsRNAs (termed dicer-substrate siRNAs, which are
processed by Dicer prior to RISC loading) (Kim et al., 2005),
and circular RNAs (including dumbbell siRNAs) (Abe et al.,
2007). Many of these RNA architectures are potent triggers of
RNAi, processed by upstream enzymes to produce siRNAs
that can be introduced into the RISC complex in similar fashion
to miRNAs. Dicer substrate siRNAs demonstrate excellent
potency, and highly effective design rules have been elucidated
(Amarzguioui et al., 2006; Amarzguioui and Rossi, 2008).
sisiRNAs have also been described, in which the siRNA pas-
senger strand consists of two shorter fragments, thermally stabi-
lized by LNA inserts, in order to create precleaved constructs
that are potent gene silencing agents with reduced OTEs (Bram-
sen et al., 2007). Antisense siRNAs, in which single stranded anti-
sense strands are introduced to trigger the RISC complex, have
also been described, although in some cases reduced potency
was observed versus standard duplex siRNAs (Martinez et al.,
2002; Haringsma et al., 2012).
In general, the first step of siRNA design (as with AON design)
is the identification of an ON sequence capable of potent knock
down of the mRNA target. The siRNA sequence selection
process can often be assisted by computational algorithmsrights reserved
Box 1. The following Relevant Topics Were Not Discussed but
Are Well-Described in the following Suggested Reviews
(1) Aptamers
Keefe et al., 2010
(2) Modulating Splicing Events
Kole et al., 2012
Saleh et al., 2012
(3) Immunostimulatory oligonucleotides
Barchet et al., 2008
(4) Clinical Trials of Olignucleotide Therapeutics
Burnett and Rossi, 2012
Sanghvi, 2011
Watts and Corey, 2012
(5) Delivery technology and strategies
Juliano et al., 2012
Rettig and Behlke, 2012
Yuan et al., 2011
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Reviewdesigned to scan an input mRNA target to identify unique
sequences that siRNAs may target with reduced chance of
creating OTEs from partial complementarity to other unintended
cellular mRNAs (Muhonen and Holthofer, 2010). Additionally, it is
wise to avoid the described immunostimulatory sequencemotifs
to reduce immunostimulation.
Chemical modifications may then be selected and applied to
the siRNA sequence (although, if a screen is performed to check
and compare potencies of many siRNA sequences targeting an
mRNA, it is often most effective to directly use chemically modi-
fied siRNAs as part of the screen). Careful consideration of which
chemical modifications to employ, and at which positions within
the duplexes they should be located, can be crucial for maintain-
ing high potency.
RNAi is triggered by short A-form dsRNAs, and RNA-like
nucleotide analogs preferring a North sugar conformation
are frequently the most beneficial modifications for siRNA
design (e.g., 20-O-Me, 20F-RNA, LNA, 20-O-MOE).
Modifications at the cleavage site of the passenger strand can
impair siRNA potency in some (but not all) cases because,
upon RISC loading, the siRNA passenger strand is typically
cleaved and removed from the guide strand (Martinez and
Tuschl, 2004; Matranga et al., 2005; Muhonen et al., 2007).
The guide strand 50 phosphate binds to the MID domain of
AGO2, and caution should be taken when using 50 modifica-
tions. Cellular kinases (i.e., CLP-1) (Weitzer and Martinez,
2007) can add this phosphate to siRNAs, but this function
can be impaired by some modifications. Chemically adding
a 50 phosphate to guide strands during synthesis can be
beneficial. Modifications preventing phosphorylation of the
siRNA sense strand 50 terminus should reduce OTEs arising
from improper RISC loading.
siRNA guide strand selection relies on duplex thermody-
namics (the strand with the least tightly-bound 50 terminus
is typically selected). Chemical modification influencing
siRNA thermodynamics to favor antisense strand loading
can help improve siRNA potency and reduce OTEs.
The siRNAguide strand is sensitive to chemicalmodifications,
especially in the seed region, and so modification strategies
typically minimize guide strand modifications, or emphasize
RNA-like analogs for the guide strand. Structural insights
revealing specific interactions between AGO2 and siRNAs
(Wang et al., 2008a, 2008b, 2009; Schirle and MacRae,
2012) can be very useful when predicting chemical modifica-
tions that will be well tolerated in siRNAs (Shukla et al., 2010).
Finally, it is important to consider the nuclease resistance, im-
munostimulatory potential, and OTEs during siRNA design. As
previously discussed, nuclease resistance can be effectively
enhanced by a wide variety of chemical modifications, and
many of the chemical modifications described in this review are
able to reduce the immunostimulatory characteristics of siRNAs
(for additional information, refer to Watts et al., 2008a; Deleavey
et al., 2009; and Whitehead et al., 2011). OTEs can also be
reduced through chemical modification. Modifications to the
sense strand 50 terminus to prevent phosphorylation and the
use of thermally stabilizing (or destabilizing) nucleoside analogs
to bias duplex thermodynamics can prevent OTEs arising from
sense strand loading in RISC. In addition, OTEs resulting whenChemistry & BiolosiRNAs act through seed region complementarity in a miRNA-
like fashion can be reduced through seed region modification
(i.e., UNA insertion in the seed region, as described above).
Conclusions
ONs, and chemically modified ON analogs, constitute an active
and truly promising field of therapeutic research. Impressive
advances have beenmade in the understanding of the biological
pathways involved inON-mediated gene silencing, and synthetic
accessibility to an extensive array of ON chemical modifications
has provided valuable tools for combating the hurdles facing ON
therapeutics. Despite these advancements, clinical success has
thus far been restricted to only two ON drugs (Vitravene and
Macugen), which has garnered some disappointment in the field.
Nevertheless, our understanding of the biological applications of
synthetic nucleic acids is continuing to advance, and the number
of ON therapeutic candidates in clinical trials has continued to
grow. Drug discovery programs can benefit from more chemical
modification tools and mechanistic understanding than ever
before. ON chemical modifications will likely play an integral
role in the development of many classes of ON therapeutics
(for additional related topics not discussed here, refer to
Box 1), and we hope this review has provided insight into the
types of availablemodifications, the biological pathways through
which they act, and the benefits that can be gained through their
use. To date, several ON-based drugs have entered mid and late
stage clinical trials (Sanghvi, 2011; Watts and Corey, 2012; Bur-
nett and Rossi, 2012), the outcomes of which will hopefully foster
confidence that ON therapeutics can make substantial contribu-
tions in the treatment of a variety of human diseases.
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